Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15

Journal of Hepatology

Volumn 66, Issue 6, 2017, Pages 1182-1192

  Zhou, Mei ^a   Luo, Jian ^a   Chen, Michael ^a   Yang, Hong ^a   Learned, R Marc ^a   DePaoli, Alex M ^a   Tian, Hui ^a   Ling, Lei ^a  

^a NGM Biopharmaceuticals Inc   (United States)

Author keywords

Bile acids and salts; Body weight; Carcinoma, hepatocellular; Cyp7a1; Diet; FGF15; FGF19; Glucose; Metabolic diseases; Obesity; Receptors, cytoplasmic and nuclear

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYCLIN A2; CYCLIN B1; CYCLIN B2; CYCLIN D1; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; GELATINASE A; GLUCOSE; GLYPICAN 3; HEMOGLOBIN A1C; INSULIN; KI 67 ANTIGEN; MACROPHAGE ELASTASE; MESSENGER RNA; PROTEIN MCL 1; STAT3 PROTEIN; SURVIVIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; ABC TRANSPORTER SUBFAMILY B; BILE ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; FIBROBLAST GROWTH FACTOR 15, MOUSE; GLYCOSYLATED HEMOGLOBIN; LEPTIN RECEPTOR; LEPTIN RECEPTOR, MOUSE; P-GLYCOPROTEIN 2; STAT3 PROTEIN, MOUSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BODY COMPOSITION; BODY WEIGHT; CALORIC INTAKE; CARCINOGENICITY; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DIET INDUCED OBESITY; ENERGY EXPENDITURE; EVOLUTION; FAT MASS; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HOMEOSTASIS; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERPHAGIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIVER CARCINOGENESIS; LIVER FIBROSIS; LUNG GAS EXCHANGE; METABOLISM; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PANCREAS ISLET BETA CELL; PHYSICAL ACTIVITY; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGONISTS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CARCINOGENESIS; DEFICIENCY; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL LIVER NEOPLASM; GENETICS; HUMAN; KNOCKOUT MOUSE; MALE; MUTANT MOUSE STRAIN; PATHOLOGY; SPECIES DIFFERENCE;

ANIMALS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY B; BILE ACIDS AND SALTS; CARCINOGENESIS; DIABETES MELLITUS, EXPERIMENTAL; FIBROBLAST GROWTH FACTORS; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; INSULIN-SECRETING CELLS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, LEPTIN; SPECIES SPECIFICITY; STAT3 TRANSCRIPTION FACTOR;

EID: 85019212277     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.01.027     Document Type: Article

References (58)

1. Beuers, U., Trauner, M., Jansen, P., Poupon, R., New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J Hepatol 62 (2015), S25–S37.
2. Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., Schoonjans, K., Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discovery 7 (2008), 678–693.
3. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
4. Hirschfield, G.M., Mason, A., Luketic, V., Lindor, K., Gordon, S.C., Mayo, M., et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology, 148(751–761), 2015, e758.
5. Mudaliar, S., Henry, R.R., Sanyal, A.J., Morrow, L., Marschall, H.U., Kipnes, M., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology, 145(574–582), 2013, e571.
6. Nevens, F., Andreone, P., Mazzella, G., Strasser, S.I., Bowlus, C., Invernizzi, P., et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. The New England Journal of Medicine 375 (2016), 631–643.
7. Ryan, K.K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature, 2014.
8. Holt, J.A., Luo, G., Billin, A.N., Bisi, J., McNeill, Y.Y., Kozarsky, K.F., et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17 (2003), 1581–1591.
9. Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C.L., McDonald, J.G., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2 (2005), 217–225.
10. Kliewer, S.A., Mangelsdorf, D.J., Bile acids as hormones: The FXR-FGF15/19 pathway. Dig Dis 33 (2015), 327–331.
11. Cicione, C., Degirolamo, C., Moschetta, A., Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology 56 (2012), 2404–2411.
12. Angelin, B., Larsson, T.E., Rudling, M., Circulating fibroblast growth factors as metabolic regulators—a critical appraisal. Cell Metab 16 (2012), 693–705.
13. Beenken, A., Mohammadi, M., The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discovery 8 (2009), 235–253.
14. Uriarte, I., Fernandez-Barrena, M.G., Monte, M.J., Latasa, M.U., Chang, H.C., Carotti, S., et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut 62 (2013), 899–910.
15. Kong, B., Huang, J., Zhu, Y., Li, G., Williams, J., Shen, S., et al. Fibroblast growth factor 15 deficiency impairs liver regeneration in mice. Am J Physiol Gastrointest Liver Physiol 306 (2014), G893–902.
16. Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331 (2011), 1621–1624.
17. Potthoff, M.J., Boney-Montoya, J., Choi, M., He, T., Sunny, N.E., Satapati, S., et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 13 (2011), 729–738.
18. Suh, J.M., Jonker, J.W., Ahmadian, M., Goetz, R., Lackey, D., Osborn, O., et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 513 (2014), 436–439.
19. Kliewer, S.A., Mangelsdorf, D.J., Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 91 (2010), 254S–257S.
20. Tomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143 (2002), 1741–1747.
21. Fu, L., John, L.M., Adams, S.H., Yu, X.X., Tomlinson, E., Renz, M., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145 (2004), 2594–2603.
22. Fang, S., Suh, J.M., Reilly, S.M., Yu, E., Osborn, O., Lackey, D., et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21 (2015), 159–165.
23. Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G.D., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160 (2002), 2295–2307.
24. Sawey, E.T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 19 (2011), 347–358.
25. Ahn, S.M., Jang, S.J., Shim, J.H., Kim, D., Hong, S.M., Sung, C.O., et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60 (2014), 1972–1982.
26. Hyeon, J., Ahn, S., Lee, J.J., Song, D.H., Park, C.K., Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig Dis Sci 58 (2013), 1916–1922.
27. Zucman-Rossi, J., Villanueva, A., Nault, J.C., Llovet, J.M., Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology, 149(1226–1239), 2015, e1224.
28. Uriarte, I., Latasa, M.U., Carotti, S., Fernandez-Barrena, M.G., Garcia-Irigoyen, O., Elizalde, M., et al. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer 136 (2015), 2469–2475.
29. Zaiss, A.K., Liu, Q., Bowen, G.P., Wong, N.C., Bartlett, J.S., Muruve, D.A., Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 76 (2002), 4580–4590.
30. Rivera, V.M., Ye, X., Courage, N.L., Sachar, J., Cerasoli, F. Jr., Wilson, J.M., et al. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci USA 96 (1999), 8657–8662.
31. Zhou, M., Wang, X., Phung, V., Lindhout, D.A., Mondal, K., Hsu, J.Y., et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res 74 (2014), 3306–3316.
32. Ritz, E., Orth, S.R., Nephropathy in patients with type 2 diabetes mellitus. New Engl J Med 341 (1999), 1127–1133.
33. Russell, D.W., Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 50:Suppl (2009), S120–125.
34. El-Serag, H.B., Hepatocellular carcinoma. New Engl J Med 365 (2011), 1118–1127.
35. Marrero, J.A., El-Serag, H.B., Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology 53 (2011), 1060–1061 [author reply 1061–1062].
36. Smit, J.J., Schinkel, A.H., Oude Elferink, R.P., Groen, A.K., Wagenaar, E., van Deemter, L., et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75 (1993), 451–462.
37. Fickert, P., Fuchsbichler, A., Wagner, M., Zollner, G., Kaser, A., Tilg, H., et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127 (2004), 261–274.
38. Lee, Y.M., Kaplan, M.M., Primary sclerosing cholangitis. New Engl J Med 332 (1995), 924–933.
39. Yu, H., Pardoll, D., Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9 (2009), 798–809.
40. Yu, H., Lee, H., Herrmann, A., Buettner, R., Jove, R., Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14 (2014), 736–746.
41. Ibrahimi, O.A., Eliseenkova, A.V., Plotnikov, A.N., Yu, K., Ornitz, D.M., Mohammadi, M., Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc Natl Acad Sci USA 98 (2001), 7182–7187.
42. Anderson, J., Burns, H.D., Enriquez-Harris, P., Wilkie, A.O., Heath, J.K., Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet 7 (1998), 1475–1483.
43. Ibrahimi, O.A., Zhang, F., Eliseenkova, A.V., Linhardt, R.J., Mohammadi, M., Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet 13 (2004), 69–78.
44. Yu, C., Wang, F., Kan, M., Jin, C., Jones, R.B., Weinstein, M., et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 275 (2000), 15482–15489.
45. Ito, S., Fujimori, T., Furuya, A., Satoh, J., Nabeshima, Y., Nabeshima, Y., Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J Clin Investig 115 (2005), 2202–2208.
46. French, D.M., Lin, B.C., Wang, M., Adams, C., Shek, T., Hotzel, K., et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS ONE, 7, 2012, e36713.
47. Xie, M.H., Holcomb, I., Deuel, B., Dowd, P., Huang, A., Vagts, A., et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11 (1999), 729–735.
48. Wu, A.L., Kolumam, G., Stawicki, S., Chen, Y., Li, J., Zavala-Solorio, J., et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med, 3, 2011, 113ra126.
49. Foltz, I.N., Hu, S., King, C., Wu, X., Yang, C., Wang, W., et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med, 4, 2012, 162ra153.
50. Perry, R.J., Lee, S., Ma, L., Zhang, D., Schlessinger, J., Shulman, G.I., FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nature Commun, 6, 2015, 6980.
51. Bookout, A.L., de Groot, M.H., Owen, B.M., Lee, S., Gautron, L., Lawrence, H.L., et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 19 (2013), 1147–1152.
52. Adams, A.C., Yang, C., Coskun, T., Cheng, C.C., Gimeno, R.E., Luo, Y., et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab 2 (2012), 31–37.
53. Ding, X., Boney-Montoya, J., Owen, B.M., Bookout, A.L., Coate, K.C., Mangelsdorf, D.J., et al. BetaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 16 (2012), 387–393.
54. Fon Tacer, K., Bookout, A.L., Ding, X., Kurosu, H., John, G.B., Wang, L., et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24 (2010), 2050–2064.
55. Schaap, F.G., van der Gaag, N.A., Gouma, D.J., Jansen, P.L., High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49 (2009), 1228–1235.
56. Zweers, S.J., Booij, K.A., Komuta, M., Roskams, T., Gouma, D.J., Jansen, P.L., et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 55 (2012), 575–583.
57. Naugler, W.E., Tarlow, B.D., Fedorov, L.M., Taylor, M., Pelz, C., Li, B., et al. Fibroblast growth factor signaling controls liver size in mice with humanized livers. Gastroenterology, 149(728–740), 2015, e715.
58. Badman, M.K., Desai, S., Laffitte, B., Decristofaro, M., Lin, T.H., Chen, J., et al. First-in-Human experience with LJN452, an orally available non-bile acid FXR agonist, demonstrates potent activation of FXR in healthy subjects. Hepatology, 64(Suppl), 2016, 16A.